Across TCGA pan-cancer cohorts, RNU6ATAC2P RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RNU6ATAC2P’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where RNU6ATAC2P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNU6ATAC2P is over-expressed in tumor.
BRCA and LUSC are the cancer types where RNU6ATAC2P tumor–normal differential expression is most reproducible.